Mirati Therapeutics, Inc. (MRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

58.66

+2.19

(+3.88%)

As of 11:58AM EDT. Market open.

Advertisement

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Neutralpattern detected

All

PR Newswire
Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Laurie Stelzer as the Company's Chief Financial Officer (CFO) effective May 16, 2022. Laurie will report to the Company's Chief Executive Officer, David Meek.
- Onto Innovation Appoints Boston Scientific Senior Financial Executive as Chief Financial Officer
  Business Wire
- Auvik Expands Leadership Team with Appointment of Bob Gault as Chief Revenue Officer
  Business Wire
Zacks
Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat
Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.
PR Newswire
Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter of 2022 and recent corporate updates.